USFDA observations for Shendra facility not critical: Wockhardt

By: |
New Delhi | Published: January 18, 2016 1:50 PM

The facility, which produces various products including ointments, capsules and tablets, currently caters to the UK and Ireland markets.

pharmaThe company’s Waluj and Chikalthana plants are already under the USFDA scanner and the company cannot export most products from these two plants to the US market. (Reuters photo)

The nine observations received by Wockhardt for its Shendra facility in Aurangabad from the US health regulator are not ‘critical’ in nature and half of the issues would be resolved in next fortnight, the company said today.

“None of the nine observations that we have received are of critical nature. We would be able to make the facility compliant for half the issues in next fifteen days and rest would be resolved in two months or so,” Wockhardt Chairman Habil Khorakiwala told reporters in a conference call.

He added that none of the observations by the US Food and Drug Administration (USFDA) were related to data integrity issues at the Shendra plant.

The facility, which produces various products including ointments, capsules and tablets, currently caters to the UK and Ireland markets.

“Other than the US market which is affected, our other businesses like India, the UK and emerging markets remain strong. We have been growing 20 per cent and above year-on- year in these markets and hope to maintain that in future too,” Khorakiwala said.

He added that the company is having an intense dialogue with the USFDA on resolving compliance issues at its various facilities like Waluj and Chikalthana in Maharashtra.

“I believe issues at some of the facilities will get resolved in next few months,” Khorakiwala said.

The company’s Waluj and Chikalthana plants are already under the USFDA scanner and the company cannot export most products from these two plants to the US market.

The company is now relying on third party manufacturing, besides some products that it is allowed to ship, to cater to the US market.

The USFDA has made nine ‘observations’ highlighting violations of its norms at Shendra plant.

The observations were made in Form 483, which is issued to a company management at the conclusion of an inspection, highlighting any conditions that may violate the Food Drug and Cosmetic (FD&C) Act and related laws.

Shares of Wockhardt were trading at Rs 1,235.50 apiece on the BSE, down 4.11 per cent from previous close.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Finmin may review capital requirement of PSU banks after second quarter
2Industry for alternate sourcing destination as cost from China not going down: Signify Innovations
3Atmanirbhar Bharat campaign is a call to foster entrepreneurship not protectionism: Venkaiah Naidu